1. Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort
- Author
-
Francesca Foglia, Luisa Costa, Antonio Del Puente, Erika Mostacciuolo, Nicolò Girolimetto, Nadia Scotti, Francesco Caso, Raffaele Scarpa, Marco Tasso, Costa, Luisa, Tasso, Marco, Scotti, Nadia, Mostacciuolo, Erika, Girolimetto, Nicolò, Foglia, Francesca, del Puente, Antonio, Scarpa, Raffaele, and Caso, Francesco
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Telemedicine ,Coronavirus disease 2019 (COVID-19) ,Immunology ,tumour necrosis factor inhibitors ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Rheumatology ,Pandemic ,medicine ,Immunology and Allergy ,Intensive care medicine ,030203 arthritis & rheumatology ,business.industry ,Outbreak ,medicine.disease ,arthritis, psoriatic ,Antirheumatic Agents ,030104 developmental biology ,biological therapy ,antirheumatic agent ,Cohort ,Antirheumatic drugs ,business - Abstract
We read with interest the article by Gupta et al 1 who reported the management of treatments for rheumatic diseases during COVID-19 pandemic among practitioners in India. In this study, the authors showed that about half of the physicians would reduce the use of biological disease-modifying antirheumatic drugs (bDMARDs) or defer specific drugs such as rituximab.1 Choices were apparently made considering possible relationships between drug mechanism of action and effect on the viral infection.1 During COVID-19 pandemic, telemedicine is emerging as a possible tool for reducing the risk of contagion and viral spread,2–4 and a useful strategy for the management of chronic diseases.5 6 As of 29 April 2020, the outbreak of COVID-19 generated 201 505 confirmed cases in Italy, with 2405 confirmed cases in Naples Metropolitan area. The objective of our study was to evaluate telemedicine when offered as part of routine care for the follow-up of patients …
- Published
- 2020
- Full Text
- View/download PDF